• Arcturus Therapeutics : Barclays cuts to underweight from equal-weight, price target to $25 from $33
  • BT Group: New Street upgraded from buy to neutral. 
  • FIGS : BofA Securities starts at buy with $42 price target
  • Flywire : Goldman Sachs starts at buy with $53 price target
  • GlaxoSmithKline: Barclays confirms its negative recommendation, keeping its Sell rating. The target price remains set at GBp 1250
  • HSBC: UBS maintains a Neutral rating. The target price remains set at GBp 450.
  • Intel : Citigroup adjusts price target to $60 from $65, maintains neutral rating
  • Ocado: Morgan Stanley upgraded from Overweight to Overweight targeting GBp 2825.
  • Paymentus : Goldman Sachs starts coverage at buy with $54 price target
  • ResMed : Needham adjusts price target to $267 from $229, buy rating kept
  • Rio Tinto: UBS upgrades from neutral to sell.
  • Singular Genomics : Goldman Sachs starts coverage at buy with $35 price target
  • SSE: Jefferies upgrades its Buy rating to Hold with a target of GBP 1680.
  • Sykes Enterprises, Incorporated : Baird downgrades stock to neutral from outperform; price target remains $54